genetic load

(redirected from Mutation load)
Also found in: Dictionary, Encyclopedia.

ge·net·ic load

the aggregate of more or less harmful genes that are carried, mostly hidden, in the genome that may be transmitted to descendants and cause morbidity and disease; in classic genetic dynamics, genetic load may be seen as undischarged genetic debts that result from previous mutations, each of which is supposed to exact an average number of lethal equivalents dependent only on the pattern of inheritance, regardless of how mild or severe the phenotype may be.

genetic load

n.
1. The relative difference between the theoretically most fit genotype within a population and the average genotype.
2. The aggregate of deleterious genes that are carried, mostly hidden, in the genomes of a population and may be transmitted to descendants.

genetic load

the average number of accumulated detrimental genes per individual within a population, including those caused by mutation and selection within a recent generation and those inherited from ancestors. Genetic load is expressed in lethal equivalents.

ge·net·ic load

(jĕ-net'ik lōd)
The aggregate of more or less harmful genes that are carried, mostly hidden, in the genome and may be transmitted to descendants and cause disease.

genetic load

The totality of abnormalities caused in each generation by defective genetic material carried in the human gene pool.

genetic load

a measurement of the amount of deleterious genes in a population, calculated as the average number of lethal equivalents per individual.
Mentioned in ?
References in periodicals archive ?
We developed a method to accurately quantify the mutant load in mtDNA; using this quantitative DHPLC analysis method, we measured the levels of heteroplasmy in several DNA samples with known mutation loads.
The data also demonstrated that patients with high levels of KRAS mutations at diagnosis, as well as elevated KRAS mutation load post-treatment, were associated with shorter overall survival times.
Clinical study results published at the 2014 ASCO Annual Meeting demonstrate that oncogene mutation load in urinary cell-free DNA, as determined using Trovagene's precision cancer monitoring technology, is significantly correlated with treatment response
NASDAQ: TROV), today announced that data from a study published in the 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology, demonstrates that oncogene mutation load in urinary cell-free DNA, as determined using the company's precision cancer monitoring technology, is significantly correlated with treatment response.
All of our procedures have been specifically optimized for somatic mutation detection, where tissue heterogeneity and low mutation loads present challenges for cancer genome screening in a discovery mode," stated Michael Nickerson, Director of Genomic Research and Biomarker Discovery at Transgenomic and co-developer of HTMA.